{"classes":[{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because no one had lost response.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"16 weeks"},{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because no one had lost response.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"32 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.66","upperLimit":"0.96","value":"0.88"}]}],"title":"48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.61","upperLimit":"0.93","value":"0.83"}]}],"title":"64 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.51","upperLimit":"0.87","value":"0.74"}]}],"title":"80 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.51","upperLimit":"0.87","value":"0.74"}]}],"title":"96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.46","upperLimit":"0.84","value":"0.69"}]}],"title":"112 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.46","upperLimit":"0.84","value":"0.69"}]}],"title":"128 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.41","upperLimit":"0.81","value":"0.65"}]}],"title":"144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.41","upperLimit":"0.81","value":"0.65"}]}],"title":"160 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.32","upperLimit":"0.73","value":"0.55"}]}],"title":"176 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.32","upperLimit":"0.73","value":"0.55"}]}],"title":"192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.32","upperLimit":"0.73","value":"0.55"}]}],"title":"208 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.32","upperLimit":"0.73","value":"0.55"}]}],"title":"224 weeks"},{"categories":[{"measurements":[{"comment":"No additional progression was experienced within population at week 240.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"240 weeks"},{"categories":[{"measurements":[{"comment":"No additional progression was experienced within population at week 256.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"256 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response).\n\nKaplan-Meier estimates are provided for duration of complete hematological remission.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization. Duration of response was pre-specified in the protocol to be analyzed for the ruxolitinib arm only considering the study design which allowed crossover for the BAT arm beginning at Week 32.","reportingStatus":"POSTED","timeFrame":"Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study","title":"Estimated Duration of the Complete Hematological Remission","type":"SECONDARY","unitOfMeasure":"probability"}